Trimi vs EverPrime
Both clinics sit in our top 10, so this page exists for readers already comparing them here. It is not written for search and is not submitted for indexing. Every figure below is read from the clinic's own page, with the date.
26 of the 51 clinics we rank are an affiliate partner. Scores come only from our published methodology. At equal displayed scores, active affiliate partners are listed first. What it changes is which clinic a promoted button points at, and every such link carries a PICK badge in the table so you can see it before you click.
Says outright that its headline is a monthly equivalent of annual billing, and prints the no-commitment rate beside it instead of leaving you to find it at checkout.
from $99/mo on a 12-month prepaid plan
Verified 2026-09-21
Enhance.MD, LLC's second storefront: compounded semaglutide at $214 a month on a 12-month plan paid up front, with a video visit, labs every six months and named pharmacies and medical groups. Its "from $115" headline needs a $99 monthly membership that brings the total back to $214, and it publishes no list of the states it serves.
from $214/mo on the 12-month plan, paid upfront
Verified 2026-10-30
Visit →Affiliate link
| Trimi | EverPrime | |
|---|---|---|
| Price | from $99/mo on a 12-month prepaid planTheir page, read 2026-09-21 | from $214/mo on the 12-month plan, paid upfrontTheir page, read 2026-10-30 |
| Price shape | one-ongoing-rate | one-ongoing-rate |
| What the price doesn’t say | $99/mo is a monthly equivalent of $1,188 billed upfront on a 12-month commitment. Not a month you can pay and stop. With no commitment it is $175/mo. Tirzepatide is $125/mo on the same 12-month basis, or $235/mo with no commitment. | $214/mo is the 12-month plan for compounded semaglutide, paid up front ($2,568 in the price list EverPrime's sign-up flow loads). Shorter plans are $224/mo (6 months), $237/mo (3 months) and $249 for one month. The "from $115" EverPrime advertises is the member price, which needs its $99/mo membership on top; the page's own member total is also $214/mo on 12 months. Read 30 October 2026. |
| What it covers | 12 months of compounded semaglutide, supplies, licensed provider care, ongoing support and free overnight shippingTheir page, read 2026-09-21 | Not published. The page does not say what the figure covers.Their page, read 2026-10-30 |
| Billed on top | Not recorded. We have not found a statement either way.Their page, read 2026-09-21 | Compare our membership plans: "Provider Oversight" ... "Treatment visits, $99/visit" in the non-member column, while the semaglutide page lists "Initial video visit with a licensed provider" and "Ongoing treatment review and provider support" as includedTheir page, read 2026-10-30 |
| Commitment | Committed term. The rate applies on a 12-month prepaid plan. Billed up front on that term. What happens after the first period: Trimi states on the page that the figures shown are monthly equivalents of annual billing, and prints the no-commitment rate ($175/mo semaglutide, $235/mo tirzepatide) next to them.Their page, read 2026-09-21 | Committed term. The rate applies on the 12-month plan, paid upfront.Their page, read 2026-10-30 |
| Routes | compounded semaglutide, compounded tirzepatide | compounded semaglutide, compounded tirzepatide, compounded semaglutide + tirzepatide, microdosing |
| Score | 7.9 | 6.8 |
What one does that the other doesn’t
Trimi
Nothing EverPrime does not also offer, on the routes we record.
EverPrime
Offers other where Trimi does not.
Who each one suits
Every line below is a difference we can measure, with the field or criterion it comes from. Where a side is empty, nothing in what we record favours it. We would rather say that than invent a reason.
Trimi
- Lower published entry figure of the two.Basis: published entry price, each in its own billing unit
- Scores clearly higher on transparency (9.0 vs 5.0).Basis: our published scoring rubric
- Scores clearly higher on pricing (8.5 vs 6.0).Basis: our published scoring rubric
EverPrime
- Only one of the two offering: other.Basis: published treatments, by drug and route
- Scores clearly higher on treatment (8.0 vs 6.5).Basis: our published scoring rubric